Monitoring Guidelines for Veozah (Fezolinetant)
Veozah requires mandatory baseline liver function testing before initiation and monthly monitoring for the first 3 months, followed by testing at 6 and 9 months due to significant hepatotoxicity risk, including postmarketing cases of drug-induced liver injury with jaundice. 1
Baseline Assessment Requirements
Before starting Veozah, you must obtain:
- Serum ALT (alanine aminotransferase)
- Serum AST (aspartate aminotransferase)
- Serum alkaline phosphatase (ALP)
- Total and direct bilirubin
Do not initiate Veozah if:
- ALT or AST ≥ 2 × ULN, OR
- Total bilirubin ≥ 2 × ULN 1
Follow-Up Hepatic Monitoring Schedule
The FDA-mandated monitoring protocol is:
- Monthly liver function tests for months 1,2, and 3
- Testing at month 6
- Testing at month 9
- Additional testing if any symptoms of liver injury develop 1
This intensive monitoring schedule stems from clinical trial data showing transaminase elevations >3 × ULN in 2.3% of patients (EAIR 2.7 per 100 person-years) and postmarketing reports of drug-induced liver injury occurring within 40 days of starting treatment 1.
Criteria for Immediate Discontinuation
Stop Veozah immediately and obtain urgent liver function tests if the patient develops:
- New onset fatigue
- Decreased appetite
- Nausea or vomiting
- Pruritus
- Jaundice
- Pale feces
- Dark urine
- Abdominal pain 1
Mandatory discontinuation criteria:
- Transaminase elevations > 5 × ULN, OR
- Transaminase elevations > 3 × ULN AND total bilirubin > 2 × ULN 1
Enhanced Monitoring Protocol
If transaminase elevations exceed 3 × ULN but don't meet discontinuation criteria, perform more frequent hepatic laboratory testing until resolution and exclude alternative causes of liver enzyme elevation 1.
Bone Mineral Density Monitoring
Veozah does not require routine bone density monitoring, which distinguishes it from GnRH antagonists like elagolix. The evidence provided focuses on elagolix (not fezolinetant/Veozah) for uterine fibroids and endometriosis, where BMD monitoring every 6 months is standard due to hypoestrogenic effects 2, 3, 4. Veozah works through a different mechanism (NK3 receptor antagonism) and does not suppress estrogen production, eliminating this concern.
Contraindications Requiring Screening
Screen for absolute contraindications before prescribing:
- Known cirrhosis (any stage)
- Severe renal impairment or ESRD
- Concomitant CYP1A2 inhibitor use (e.g., fluvoxamine, ciprofloxacin) 1
Practical Monitoring Pitfalls
The most critical pitfall is inadequate adherence to the monthly monitoring schedule during the first 3 months. Postmarketing hepatotoxicity cases occurred within 40 days of initiation 1, making early detection essential. Real-world data shows only 42% of persistent users received appropriate liver function testing in the first 3 months 5, representing a significant safety gap.
Ensure patients understand they must discontinue immediately with any symptoms suggesting liver injury—waiting for scheduled monitoring could delay recognition of serious hepatotoxicity 1.